US equities
|
NVDA
$241.57
▲+1.12%
SPCX
$173.85
▲+1.61%
MU
$1,062.47
▼-0.14%
AMD
$655.01
▲+3.68%
MRVL
$289.32
▲+6.66%
SNDK
$1,669.35
▼-2.04%
AVGO
$378.03
▲+4.28%
TSLA
$381.21
▲+0.65%
NVDA
$241.57
▲+1.12%
SPCX
$173.85
▲+1.61%
MU
$1,062.47
▼-0.14%
AMD
$655.01
▲+3.68%
MRVL
$289.32
▲+6.66%
SNDK
$1,669.35
▼-2.04%
AVGO
$378.03
▲+4.28%
TSLA
$381.21
▲+0.65%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
NanoViricides, Inc. Common Stock
(NY:
NNVC
)
1.390
-0.060 (-4.14%)
Delayed Quote
Updated: 11:39 AM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NanoViricides, Inc. Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model
June 20, 2024
Via
ACCESSWIRE
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
June 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
June 14, 2024
Via
Benzinga
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
June 11, 2024
Via
ACCESSWIRE
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
June 04, 2024
Via
ACCESSWIRE
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
May 29, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
June 12, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
June 10, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
June 06, 2024
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
June 05, 2024
Via
Benzinga
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
May 20, 2024
Via
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report
May 15, 2024
Via
ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against RSV
May 14, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
June 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
June 03, 2024
Via
Benzinga
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
May 29, 2024
Via
AB Newswire
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
May 23, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
May 16, 2024
Via
Benzinga
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
May 08, 2024
Via
ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
May 06, 2024
Via
ACCESSWIRE
NNVC Stock Earnings: Nanoviricides Beats EPS for Q3 2024
↗
May 15, 2024
NNVC stock results show that Nanoviricides beat analyst estimates for earnings per share the third quarter of 2024.
Via
InvestorPlace
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
May 10, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
↗
May 06, 2024
Via
Benzinga
3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire
↗
May 02, 2024
Discover three nanotech stocks poised for explosive growth in a booming market. Explore their potential for massive returns.
Via
InvestorPlace
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
April 30, 2024
Via
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
February 15, 2024
Via
ACCESSWIRE
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
February 01, 2024
Via
ACCESSWIRE
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
↗
January 31, 2024
Colds, flu and RSV aren't the only viral illnesses people have to worry about this winter. A new variant of COVID-19 is rapidly spreading, reminding the world of just how dangerous this virus is.
Via
Benzinga
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
January 29, 2024
Via
ACCESSWIRE
NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024
↗
January 08, 2024
NanoViricides, Inc. (NYSE American: NNVC) recently announced that it is presenting at Biotech Showcase™ 2024. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
